BCM
KURA icon

Bayesian Capital Management’s Kura Oncology KURA Stock Holding History

Bayesian Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,026
Closed -$128K – 902
2023
Q3 		$128K Buy
+14,026
New +$142K 0.01% 589

Other funds holding KURA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Bayesian Capital Management's KURA Position: Q4 2023 in Review

Bayesian Capital Management sold out of Kura Oncology (KURA) in Q4 2023, closing a stake of 14,026 shares — an estimated $128K sold.

Bayesian Capital Management first reported a position in KURA in Q3 2023 and held it in 1 quarter. The position peaked at $128K in Q3 2023. 140 funds tracked by Wall St. Rank hold KURA as of Q4 2023.

  • Bayesian Capital Management reported no remaining Kura Oncology position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 14,026 Kura Oncology shares in Q4 2023, an estimated $128K.
  • Bayesian Capital Management first reported a position in Kura Oncology in Q3 2023 and held it in 1 quarter.
  • Bayesian Capital Management's Kura Oncology position peaked at $128K in Q3 2023.
  • 140 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.